Regeneron Pharmaceuticals, Inc. vs Moody's Corporation
Comparaison de la capitalisation boursière au fil du temps
Regeneron Pharmaceuticals, Inc.
$81.5B
Rang #193
Moody's Corporation
$82.6B
Rang #191
Capitalisation boursière au fil du temps
Moments clés
- Regeneron Pharmaceuticals, Inc. a dépassé Moody's Corporation avant 1995
- Moody's Corporation a dépassé Regeneron Pharmaceuticals, Inc. avant 1997
- Regeneron Pharmaceuticals, Inc. a dépassé Moody's Corporation avant 2000
- Moody's Corporation a dépassé Regeneron Pharmaceuticals, Inc. avant 2002
- Regeneron Pharmaceuticals, Inc. a dépassé Moody's Corporation avant 2011
- Moody's Corporation a dépassé Regeneron Pharmaceuticals, Inc. avant 2019
- Regeneron Pharmaceuticals, Inc. a dépassé Moody's Corporation avant 2020
- Moody's Corporation a dépassé Regeneron Pharmaceuticals, Inc. avant 2021
- Regeneron Pharmaceuticals, Inc. a dépassé Moody's Corporation avant 2022
- Moody's Corporation a dépassé Regeneron Pharmaceuticals, Inc. avant 2024
Comparaison année par année
| Année | Regeneron Pharmaceuticals, Inc. | Moody's Corporation | Leader |
|---|---|---|---|
| 2026 | $81.5B | $82.6B | Moody's Corporation |
| 2025 | $79.3B | $88.8B | Moody's Corporation |
| 2024 | $72.8B | $81.7B | Moody's Corporation |
| 2023 | $89.7B | $66.9B | Regeneron Pharmaceuticals, Inc. |
| 2022 | $73.7B | $47.2B | Regeneron Pharmaceuticals, Inc. |
| 2021 | $64.5B | $65.6B | Moody's Corporation |
| 2020 | $49.4B | $48.4B | Regeneron Pharmaceuticals, Inc. |
| 2019 | $38.4B | $39.3B | Moody's Corporation |
| 2018 | $38.2B | $22.9B | Regeneron Pharmaceuticals, Inc. |
| 2017 | $38.4B | $23.9B | Regeneron Pharmaceuticals, Inc. |
| 2016 | $37.5B | $15.1B | Regeneron Pharmaceuticals, Inc. |
| 2015 | $55.5B | $15.8B | Regeneron Pharmaceuticals, Inc. |
| 2014 | $41.9B | $14.9B | Regeneron Pharmaceuticals, Inc. |
| 2013 | $28.1B | $12.0B | Regeneron Pharmaceuticals, Inc. |
| 2012 | $17.5B | $7.6B | Regeneron Pharmaceuticals, Inc. |
| 2011 | $5.7B | $5.0B | Regeneron Pharmaceuticals, Inc. |
| 2010 | $3.4B | $3.9B | Moody's Corporation |
| 2009 | $2.5B | $3.9B | Moody's Corporation |
| 2008 | $1.9B | $2.8B | Moody's Corporation |
| 2007 | $2.5B | $5.0B | Moody's Corporation |
| 2006 | $2.1B | $9.6B | Moody's Corporation |
| 2005 | $1.6B | $8.5B | Moody's Corporation |
| 2004 | $941.1M | $6.0B | Moody's Corporation |
| 2003 | $1.5B | $4.2B | Moody's Corporation |
| 2002 | $1.9B | $2.8B | Moody's Corporation |
| 2001 | $2.9B | $2.7B | Regeneron Pharmaceuticals, Inc. |
| 2000 | $3.6B | $1.7B | Regeneron Pharmaceuticals, Inc. |
| 1999 | $1.3B | $1.5B | Moody's Corporation |
| 1998 | $753.6M | $1.6B | Moody's Corporation |
| 1997 | $874.9M | $1.6B | Moody's Corporation |
| 1996 | $1.6B | $1.2B | Regeneron Pharmaceuticals, Inc. |
| 1995 | $1.3B | $1.2B | Regeneron Pharmaceuticals, Inc. |
| 1994 | $306.5M | $1.1B | Moody's Corporation |